Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia

Soheil Meshinchi, Robert J. Arceci

Research output: Contribution to journalReview article

Abstract

Acute myeloid leukemia (AML) has posed significant therapeutic challenges to pediatric oncologists. Despite intensive therapy, half of the children with AML relapse and die from their disease. Efforts to identify risk factors in AML are directed toward defining populations who may benefit from alternative therapies. Patients at lower risk for relapse may benefit from treatment de-escalation, sparing them adverse side effects. Management of high-risk patients may prove more difficult, as the nearly myeloablative nature of AML therapy leaves little room for therapy escalation short of stem cell transplantation. This review evaluates prognostic factors in pediatric AML and discusses the feasibility of using these factors in risk-adapted therapy regimens.

Original languageEnglish (US)
Pages (from-to)341-355
Number of pages15
JournalOncologist
Volume12
Issue number3
DOIs
StatePublished - Apr 17 2007

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia'. Together they form a unique fingerprint.

  • Cite this